Aptevo Therapeutics Inc. (APVO) Description, Stock price, News & Info.

#ThinkSabio Latest News

$APVO – Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection